fda compounding semaglutide news october 2025 September 2, 2025: U.S. restrictions have stemmed a flood of compounded and tirzepatide – Partnership for Safe Medicines FDA Ban on Compounded GLP-1

More Than Appetite Control Weight Loss Is Not Only About Eating Less One of the most interesting points discussed at the conference was that tirzepatide is not only about eating less

1 Introduction Alzheimers disease (AD) is a progressive neurodegenerative condition characterized by memory loss and cognitive dysfunction ( The glucagon-like peptide-1 receptor (GLP-1R) is a key target for diabetes mellitus (DM) treatment, and GLP-1R agonists are pharmaceutical compounds employed in the treatment of DM

Here is a summary of the data for Alabama: Medicaid spending on GLP-1s (past 12 months): $43,100,970 Medicaid spending on GLP-1s (YoY change): +107% Medicaid spending on GLP-1s per enrollee (past 12 months): $55 Total Medicaid enrollment: 787,325 Wegovy coverage (obesity-indicated): Yes Zepbound coverage (obesity-indicated): No Saxenda coverage (obesity-indicated): No Ozempic coverage (Type 2 diabetes-indicated): Yes Mounjaro coverage (Type 2 diabetes-indicated): Yes Rybelsus coverage (Type 2 diabetes-indicated): Yes For reference, here are the statistics for the entire United States: Medicaid spending on GLP-1s (past 12 months): $3,452,602,033 Medicaid spending on GLP-1s (YoY change): +142% Medicaid spending on GLP-1s per enrollee (past 12 months): $48 Total Medicaid enrollment: 72,429,055 Wegovy coverage (obesity-indicated): 34 states Zepbound coverage (obesity-indicated): 16 states Saxenda coverage (obesity-indicated): 19 states Ozempic coverage (Type 2 diabetes-indicated): 51 states* Mounjaro coverage (Type 2 diabetes-indicated): 46 states* Rybelsus coverage (Type 2 diabetes-indicated): 46 states *Including District of Columbia For more information, a detailed methodology, and complete results, see Which State Medicaid Programs Cover GLP-1s for Weight Loss & How Much Are They Spending

At Everest Regenerative Medicine in West Fargo, ND, conversations about medical weight loss should account for real-life factors like nutrition, hydration, sleep, alcohol use, and long-term metabolic health

Under her leadership, the program has published multiple groundbreaking studies in collaboration with the Division of Research, highlighting the implications of substance use in pregnancy on maternal and neonatal health outcomes

The challenge here is that reducing the risk of future adverse outcomes cannot be measured in the present of any particular patient